Israel Corp (ILCO) AI Stock Analysis

• Market Cap: 8.51B
• Dividend Yield: 0.61%
• Average Volume (3M): 9.79K
• Price to Earnings (P/E): 14.1
• Beta (1Y): 1.37
• Revenue Growth: -4.29%
• EPS Growth: -24.35%
• Country: IL
• Employees: 13,067
• Sector: Basic Materials
• Sector Strength: 69
• Industry: Chemicals - Specialty
• EPS (TTM): 1687.20
• Shares Outstanding: 7,572,548
• 10 Day Avg. Volume: 8,103
• 30 Day Avg. Volume: 9,793
• PEG Ratio: -0.29
• Price to Book (P/B): 0.88
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 4.65
• Enterprise Value/Market Cap: 0.34
• Enterprise Value/Revenue: 0.10
• Enterprise Value/Gross Profit: 1.29
• Enterprise Value/Ebitda: 0.51
• 1Y Price Target: 131,763.04
• Price Target Upside: 16.16% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 71 Outperform
• Price Target: 130,235 ▲(14.82%Upside)

The overall stock score reflects solid financial stability and positive technical indicators. The company benefits from effective cash flow management and a robust balance sheet, though there is room for improvement in net profit margins and return on equity. The technical outlook is favorable, but valuation suggests fair pricing with limited dividend yields.

Israel Corp Business Overview & Revenue Model

Company Description

Israel Corp (ILCO) is a leading holding company based in Israel, focusing on a diversified portfolio of industrial sectors. It operates mainly in the fields of chemicals, energy, and shipping, with a presence in various international markets. Through its subsidiaries, ILCO is involved in the production and distribution of essential chemicals, energy resources, and maritime transportation services.

How the Company Makes Money

Israel Corp makes money through its diverse range of investments and subsidiaries. The company generates revenue from its chemical segment, primarily via its subsidiary ICL Group, which produces and markets fertilizers, industrial products, and performance products. In the energy sector, ILCO earns income through its holdings in Oil Refineries Ltd, contributing to its earnings from refining and selling petroleum products. Additionally, the shipping segment, including its subsidiary ZIM Integrated Shipping Services, provides ILCO with revenue from maritime transportation and logistics services. These revenue streams are supported by strategic partnerships and a global presence that enhance market reach and efficiency.

Israel Corp Financial Statement Overview

Summary

Israel Corp displays sound financial health with stable operational margins and effective cash flow management. The company maintains a strong balance sheet with low leverage. However, opportunities exist to improve net profit margins and return on equity.

Income Statement

The company shows a steady gross profit margin at around 32.8% for TTM, indicating a stable cost management. However, the net profit margin for the TTM is relatively low at 2.4%, reflecting pressure on bottom-line profitability. Revenue growth has been inconsistent, with a significant decline in 2022 and a modest recovery thereafter. EBIT and EBITDA margins are stable at 10.8% and 20.5% respectively for TTM, showing consistent operational efficiency.

Balance Sheet

The balance sheet reflects a strong equity position with an equity ratio of 22.3% for TTM, indicating a decent level of financial stability. The debt-to-equity ratio stands at 0.27, showing effective leverage management. Return on equity is moderate, at 5.7% for TTM, suggesting room for improvement in generating returns on shareholder investments.

Cash Flow

The cash flow position is robust, with a strong operating cash flow to net income ratio of 8.0 for TTM, indicating excellent cash generation relative to reported earnings. Free cash flow has shown variability but is positive, with a slight decline in the most recent period. The free cash flow to net income ratio is high at 3.34, reflecting strong cash flow performance relative to earnings.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.84B	7.54B	10.02B	6.96B	5.04B
Gross Profit	2.25B	2.67B	5.03B	2.61B	1.49B
EBITDA	1.43B	1.71B	4.06B	1.93B	711.00M
Net Income	190.00M	273.00M	953.00M	88.00M	-173.00M
Balance Sheet
Total Assets	12.49B	12.89B	13.09B	12.26B	11.08B
Cash, Cash Equivalents and Short-Term Investments	1.32B	1.57B	1.56B	1.14B	1.06B
Total Debt	604.00M	1.05B	3.96B	4.61B	4.44B
Total Liabilities	6.11B	6.53B	7.24B	7.98B	7.32B
Stockholders Equity	2.82B	2.78B	2.46B	1.54B	1.40B
Cash Flow
Free Cash Flow	710.00M	1.04B	1.46B	497.00M	290.00M
Operating Cash Flow	1.42B	1.82B	2.21B	1.11B	917.00M
Investing Cash Flow	-343.00M	-1.10B	-748.00M	-830.00M	-398.00M
Financing Cash Flow	-979.00M	-931.00M	-1.16B	-403.00M	-192.00M

Israel Corp Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 113430.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:ILCO, the sentiment is Neutral. The current price of 113430 is below the 20-day moving average (MA) of 115813.50, below the 50-day MA of 115100.40, and above the 200-day MA of 101577.37, indicating a neutral trend. The MACD of 690.36 indicates Positive momentum. The RSI at 45.07 is Neutral, neither overbought nor oversold. The STOCH value of 15.72 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IL:ILCO.

Israel Corp Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KAFR	80 Outperform	663.38M	9.80		2.98%	15.45%	26.50%
POLP	75 Outperform	1.15B	13.04		3.45%	1.43%	-0.59%
RIMO	75 Outperform	461.87M	11.06		9.53%	-10.12%	5.34%
TRPZ	72 Outperform	4.78B	79.59		0.61%	54.19%	28.29%
ILCO	71 Outperform	8.51B	14.13	5.77%	0.61%	-4.29%	-24.35%
Sector *	62 Neutral	$10.32B	9.99	0.09%	2.85%	2.25%	-33.42%

Israel Corp Corporate Events

Israel Corp Clarifies Director’s Involvement in Unrelated Legal Matter

Israel Corp has announced that a statement of claims has been filed against Mr. Yaakov Amidror, an external director at the company, by the Securities Authority. This is in relation to his role as chairman of the board at Next Gen Biomed Ltd. The company clarified that it has no connection to Next Gen Biomed Ltd or the ongoing administrative enforcement procedure.